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Abstract
MicroRNA (miRNA) expression varies in association with different tissue types and in diseases. 
Having been found in body fluids including blood and cerebrospinal fluid (CSF), miRNAs 
constitute potential biomarkers. CSF miRNAs have been proposed as biomarkers for 
neurodegenerative diseases; however, there is a lack of consensus about the best candidate miRNA 
biomarkers and there has been variability in results from different research centers, perhaps due to 
technical factors. Here, we sought to optimize technical parameters for CSF miRNA studies. We 
examined different RNA isolation methods and performed miRNA expression profiling with 
TaqMan® miRNA Arrays. More specifically, we developed a customized CSF-miRNA low-
density array (TLDA) panel that contains 47 targets: miRNAs shown previously to be relevant to 
neurodegenerative disease, miRNAs that are abundant in CSF, data normalizers, and controls for 
potential blood and tissue contamination. The advantages of using this CSF-miRNA TLDA panel 
include specificity, sensitivity, fast processing and data analysis, and cost effectiveness. We 
optimized technical parameters for this assay. Further, the TLDA panel can be tailored to other 
specific purposes. We tested whether the profile of miRNAs in the CSF resembled miRNAs 
isolated from brain tissue (hippocampus or cerebellum), blood, or the choroid plexus. We found 
that the CSF miRNA expression profile most closely resembles that of choroid plexus tissue, 
underscoring the potential importance of choroid plexus-derived signaling through CSF miRNAs. 
In summary, the TLDA miRNA array panel will enable evaluation and discovery of CSF miRNA 
biomarkers and can potentially be utilized in clinical diagnosis and disease stage monitoring.
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Introduction
MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression 
posttranscriptionally. MiRNAs have been implicated in neurodegenerative diseases, such as 
Alzheimer’s disease (AD) [1–4]. MiRNAs are expressed in virtually all known mammalian 
cells and can be found in body fluids including serum, cerebrospinal fluid (CSF), saliva, 
urine, and breast milk [5], providing a potential opportunity to monitor disease presence and 
severity. Studies have shown that miRNAs in serum and plasma are stable at room 
temperature for several days and even resistant to RNase treatment [6]. Furthermore, they 
are also easier to detect and quantify compared to many protein biomarkers [7]. Thus, 
biofluid miRNAs are good candidates for biomarkers.
Despite extensive studies, no miRNA has been firmly established as a clinically relevant 
biomarker. Challenges include the complexity of the pathophysiological conditions (various 
stages of disease and comorbid pathologies) and also probably heterogeneous human cohorts 
[8, 9]. This is particularly true for neurodegenerative diseases. Furthermore, preanalytical 
and analytical factors such as sampling methods, specimen storage, RNA isolation and 
detection platform, and data normalization all contribute to the mixed outcomes of the 
analysis [10–12].
CSF provides a special context for biomarkers. Already used as an AD biomarker detecting 
Aβ, tau, and other analytes, CSF can be obtained via routine lumbar puncture. This clear 
proteinaceous fluid is normally in direct contact with the brain after being produced in the 
choroid plexus, which exchanges chemicals, proteins, electrolytes, and other molecules with 
the blood stream. Thus, it is a critical context for searching biomarkers in association with 
CNS diseases.
Prior studies have analyzed CSF miRNA expression in association with CNS diseases (see 
for example [13–19]). These studies employed various isolation and detection methods, 
mostly array and deep sequencing-based profiling. Prior studies generated valuable 
information in searching for reliable biomarkers. However, contradictory results were also 
reported possibly because of biological complexity and the various study designs and 
methodological factors. Furthermore, array- and sequencing-based analysis generally have 
poorer sensitivity and higher variability for low-quantity RNA inputs, which are typical in 
clinic-derived CSF samples.
Here, we describe a custom-made miRNA RT-qPCR panel that can overcome some of the 
aforementioned shortcomings in CSF miRNA analysis. The goal was to produce a relatively 
economic platform that includes miRNAs known to be present in CSF and include those 
miRNAs that previously were implicated as possible biomarkers. We also used this panel to 
test whether the miRNA profile of CSF more closely resembles RNA isolated from blood, 
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the choroid plexus, or brain tissues derived from the University of Kentucky AD Center 
(UK-ADC) biobank.
Materials and Methods
Human Cerebrospinal Fluid, Brain Tissues, and Blood Samples
Human CSF and tissues used in this work were obtained from the UK-ADC biobank and 
analyzed in compliance with University of Kentucky Institutional Review board protocol. 
Clinical lumbar puncture-derived CSF, blood samples, and snap-frozen brain tissues from 
individuals obtained at autopsy, as described previously [20, 21], were coded anonymously.
RNA Isolation from Brain Tissues and Blood
Total RNA was extracted from human tissues and blood samples using TRIzol LS reagent 
(Thermo Fisher Scientific) following the modified procedure described previously [3, 22, 
23]. The RNA concentrations and purity were determined using a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific).
Testing CSF RNA Isolation Methods
For the study of RNA isolation technical parameters, ten lumbar puncture-harvested CSF 
samples were mixed and spun at 3000 × g for 5 min. Aliquots of 200 μl supernatant from the 
mixed sample were used for each RNA isolation procedure. Four replicates were evaluated 
for each method. Total RNA was extracted and compared using commercially available kits: 
MagMAX™ mirVana™ Total RNA Isolation Kit (Thermo Fisher Scientific), miRCURY™ 
RNA Isolation Kit–Biofluids (Exiqon), miRNeasy Serum/Plasma Kit (QIAGEN), 
NucleoSpin miRNA Plasma (MACHEREYNAGEL), PureLink™ RNA Mini Kit (Thermo 
Fisher Scientific), and TRIzol LS reagent (Thermo Fisher Scientific). RNA isolations were 
carried out following manufacturers’ instructions except for TRIzol LS reagent which was 
done exactly as described previously [3, 22, 23]. RNA isolation experiments were performed 
with or without nucleic acid carriers, glycogen, and bacteriophage MS2 RNA (both from 
Roche). RNA was eluted or dissolved with 30 μl of nuclease-free water containing RNAsin 
(0.5 U/μl, Promega). After a preliminary comparison by single-tube TaqMan® miRNA 
assays (data not shown), three kits including miRCURY™ RNA Isolation Kit–Biofluids, 
miRNeasy Serum/Plasma Kit, and TRIzol LS reagent were selected for further assessments 
by miR-15/107 TaqMan® Low-Density Array (TLDA) analysis [24].
CSF miRNA Profiling Using TaqMan® Array Human MicroRNA A+B Cards Set v3.0
Clinical CSF samples were collected as described above from additional four controls and 
four AD patients and the RNA subjected to TaqMan® Array analysis using Human 
MicroRNA A+B Cards Set v3.0 (Life Technologies). CSF RNA was isolated using Exiqon’s 
miRCURY™ RNA Isolation Kit (Biofluids) following manufacturer’s protocol. Briefly, 200 
μl of CSF was transferred to a fresh tube after centrifuge at 3000 g for 5 min; 60 μl of Lysis 
Solution BF was added to the supernatant following a 5-s vortex. After a 3-min incubation, 1 
μg of bacteriophage MS2 RNA (carrier, Roche) and 3.5 μl of Cel-miR-39-3p (spike-in RNA, 
QIAGEN) at 1.6 × 108 copies/μl was added to the mixture. Protein Precipitation Solution BF 
(20 μl) was added, vortex, incubated for 1 min, and centrifuged. The clear supernatant was 
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transferred to a fresh collection tube with addition of 270 μl isopropanol and mixed. Column 
binding, washing, and drying were conducted as instructed by the protocol, and RNA was 
eluted with 30 μl of nuclease-free water containing 0.5 U/μl RNAsin (Promega). Next, equal 
volume of total CSF RNA (3 μl) was reverse transcribed using the TaqMan® MicroRNA 
Reverse Transcription Kit (Life Technologies) with Megaplex™ Primer Pools, Human Pool 
A and B, respectively (Life Technologies). The resulting complementary DNA (cDNA) was 
preamplified using corresponding Human Pool A or B Megaplex™ PreAmp Primers (Life 
Technologies) before running the qPCR Array. qPCR was carried out on the ViiA™ 7 Real-
Time PCR System and quantitative PCR cycle (Cq) was determined using ViiA 7 RUO 
software (Life Technologies) with automatic baseline and a fixed threshold set at 0.15.
TaqMan® Low-Density Array (TLDA) Analysis
Two separate sets of custom-developed TLDA cards were used in the study: miR-15/107 
TLDA cards and CSF-miRNA TLDA cards. MiR-15/107 TLDA cards have been described 
in detail previously [24]. The CSF-miRNA TLDA card incorporated a combination of 
miRNAs related to CSF and neurodegenerative diseases and the miRNA selection was 
discussed in “Results.” Standard manufacturer’s protocol was followed for all TLDA cards. 
Briefly, 3 μl of CSF RNA or tissue RNA (at 10 ng/μl) was reverse transcribed using 
TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies) with pooled specific 
RT primers for each panel. An aliquot of RT product was then preamplified using TaqMan® 
PreAmp Master Mix (Life Technologies) with pooled preamplification primers (Life 
Technologies). RT products with or without preamplification were served as templates. 
Premixed template and TaqMan® Universal PCR Master Mix (No AmpErase UNG, Life 
Technologies) were transferred to each port of TLDA cards and loaded to each well by 
spinning the cards in a centrifuge according to the manufacturer’s instructions. qPCR was 
performed using ViiA™ 7 Real-Time PCR System (Life Technologies).
TaqMan® Single-Tube RT-qPCR for Individual miRNAs
Individual miRNA and spike-in Cel-miR-39 were subjected to single-tube TaqMan® RT-
qPCR assay (LifeTechnologies) according to the manufacturer’s instructions. Equal volume 
of CSF RNA (3 μl) for reverse transcription and qPCR was performed in triplicate.
Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
was followed throughout all the RT-qPCR procedure [25].
Data and Statistical Analysis
Raw PCR Cq values from custom or inventory array cards were first determined using ViiA 
7 RUO software (Life Technologies) with automatic baseline and threshold set at 0.15. Data 
that failed QC, including those such as bad passive reference signal and failed in exponential 
algorithm and thresholding algorithm (amplification too early or too late, low amplification 
or no amplification), were treated as undetectable in the analysis. Outliers such as a data 
point that is much higher or much lower in Cq among replicates in the data set was also 
examined manually, and an amplification curve that was abnormal (i.e., flat curve which 
resulted in low Cq) was also treated as undetectable. DataAssist® software (Life 
Technologies) was employed to further analyze miRNA array data. A Cq value equal to or 
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greater than 32 was considered as undetectable. The global mean normalization method [26] 
was selected and a Cq cutoff was set at 35 for inventory and miR-15/107 custom TLDA 
cards and 32 for CSF-miRNA TLDA cards (e.g., a Cq value equal to or more than 32 was 
considered as undetectable in custom CSF-miRNA TDLA arrays). Correlation coefficient 
(R2) of the datasets from customized CSF panel and inventory array cards was obtained 
using linear regression function.
Welch’s two-sample t test was used to evaluate the difference of the mean and total qPCR 
array Cq data between the control and AD groups. To determine the differential expression 
pattern between CSF and tissues, array data were evaluated using an unpaired Student’s t 
test. Hierarchical clustering based on the similarity of miRNA expression patterns was 
calculated using Pearson’s distance-Average Linkage. Benjamini–Hochberg tests were used 
to control false discovery rate (FDR). p value that is less than 0.05 was considered as 
statistically significant.
Correlation coefficient (R2) of miRNA expression pattern between CSF and each individual 
tissue group was obtained using linear regression function, and evaluation of correlations 
between CSF and various nonindependent tissues was done using confidence intervals 
according to the method described by Zou [27].
Results
Empirical Evaluation of CSF RNA Isolation Methods
Isolating quality RNA is a critical first step in studying CSF miRNA. The three most 
effective kits in our hands were as follows: Exiqon’s miRCURY™ RNA Isolation Kit–
Biofluids; QIAGEN’s miRNeasy Serum/Plasma Kit; and Thermo Fisher Scientific’s 
TRIzol® LS Reagent. Because the content of RNA is generally very low in clinical CSF 
samples, NanoDrop or other methods of concentration measurements were not sensitive 
enough for assessing the quantity and quality of CSF RNA. Instead, we used customized 
miR-15/107 TaqMan® Low-Density Array (TLDA, format 24; Life Technologies) [24] to 
assess the quantity and quality of CSF RNA isolations. Figure 1 illustrates the procedure 
used in evaluating CSF RNA isolation. RNA quantity and quality were defined by the 
following standards: (1) low quantification cycle (Cq); (2) high ΔCq above the background; 
(3) low technical variability (standard deviation) among replicates.
Nucleic acid carriers are additives that enhance the yield of RNA isolation, which is 
particularly helpful in biological samples with low-concentration RNAs. We evaluated two 
different carriers, glycogen and bacteriophage MS2 RNA. Both MS2 RNA and glycogen 
carriers enhanced the RNA yield (Suppl. Table 1), with MS2 RNA carrier slightly increasing 
technical background levels (Table 1). Next, we tested the consistency of each RNA 
isolation method. Four technical replicate isolations were carried out and TLDA array 
qPCRs were performed. All three tested methods gave high consistency and there was no 
statistically significant difference among the isolation methods tested although some trends 
were noted (Fig. 2a, Table 2). TRIzol isolation seemed to perform better as judged by the 
trends for lower background (high Cq in background), higher ΔCq above background, and 
better consistency among replicate isolations (smaller STDEV). When comparing qPCR Cq 
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from different isolation methods, they generally agreed with each other, but were far from 
perfect (Fig. 2b). From our data, it is clearly important to use one selected method 
consistently throughout a group of samples. On the other hand, when validating the results, 
it may be necessary to use a different approach, to avoid the inherent bias or false positives/
negatives generated from the same isolation and detection systems.
In summary, the different methods appear to each have separate strengths and weaknesses 
(Table 3). Overall, TRIzol LS provided slightly more consistent results but it involves a 
phenol/chloroform step and is technically challenging to obtain a “clean” prep with that 
method. By contrast, miRCURY stands out for its easy and fast isolation procedure, good 
quality/quantity RNA, and a lack of organic solvent step in the process. We selected the 
miRCURY method with MS2 RNA carrier for further studies.
Preamplification Increases the Sensitivity and Uniformity of CSF miRNA Detection
We employed TaqMan® miRNA single-tube assays and TLDA panel to assess CSF 
miRNAs. Mindful of the challenge of combining both high technical sensitivity and low 
sample-to-sample variability, TaqMan® assays were tested with or without preamplification. 
Preamplification is an intermediate step after reverse transcription and before qPCR in 
which cDNA can be enriched over several orders of magnitude, theoretically without 
disturbing the relative expression of the different miRNAs (Suppl. Fig. 1 and [28]). For 
detecting minute quantities of miRNA, preamplification greatly enhances the detection 
power of qPCR and data uniformity [28]. As showed in Fig. 3, Cq of most miRNAs in the 
miR-15/107 TLDA panel fell to the background levels without preamplification. In contrast, 
preamplification improved detection sensitivity by several Cq values. Thus, for most of the 
miRNA species, preamplification is a necessary step when assessing CSF RNA using RT-
qPCR.
CSF miRNA Exploratory Profiling Using TaqMan® Array Human MicroRNA A+B Cards Set 
v3.0
In order to better control technical variables and to assess the repertoire of miRNAs 
detectable with TaqMan® RT-qPCR assays in CSF, we ran a set of discovery (exploratory) 
profiling arrays using clinical CSF samples from four controls and four AD patients. Total 
RNA was extracted from CSF using Exiqon’s miRCURY™ RNA Isolation Kit (Biofluids). 
MS2 RNA was used as additive and C. elegans Cel-miR-39 was spiked in to monitor the 
isolation efficiency. TaqMan® RT-qPCR of Cel-miR-39 using the same volume (3 μl) of 
isolated RNAs gave similar Cq values across eight isolates with a standard deviation of 0.2 
(Suppl. Table 2), indicating a consistent RNA isolation of all CSF samples. This was also 
evident by NanoDrop estimation of RNA concentrations.
In the TaqMan® RT-qPCR miRNA results, a miRNA with Cq equal to or more than 35 was 
considered as undetectable. A miRNA was determined to be detectable in CSF if it was 
present in more than three arrays (out of eight). Using this cutoff, 130 and 63 miRNAs were 
detected in Card A and Card B, respectively. There was a small but statistically significant 
difference in median Cq of miRNA expression between the control and AD groups (Fig. 4). 
Total miRNA content (represented by total Cq values) was also less abundant in AD group 
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(higher Cq value). However, most individual miRNAs were not expressed differently 
between the samples (using the criterion of fold change ≥ 2, p ≤ 0.05), with the important 
caveat of the small sample size (Suppl. Excel file 1).
Most abundant miRNAs in CSF were identified by ranking average Cq values of all samples. 
The most abundant miRNAs (Table 4) included miR-204, miR-1274B, miR-16, miR-146a, 
miR-150, miR-223, miR-17, and miR-21 as described previously [13, 19]. The complete list 
of all detectable miRNAs can be found in supplemental Excel file 2.
The exploratory profiling also enabled us to select potential CSF-specific “housekeeping” 
miRNAs for data normalization. Table 5 shows miRNAs displaying relatively constant levels 
across both the control and AD groups and within the group as judged by their smaller 
standard deviations.
A CSF-miRNA Panel to Study miRNAs in the Context of Alzheimer’s Disease
We chose customized TaqMan® miRNA RT-qPCR low-density array format 48 (Life 
Technologies) as the platform for studying CSF miRNAs relevant to AD. This PCR-based 
expression platform can simultaneously analyze eight samples and accommodate a total of 
47 miRNAs plus one mandatory control (U6) per sample. The following criteria were used 
to select miRNAs for the panel (Table 6): (1) miRNA is detectable in CSF based on our 
profiling and existing literature; (2) miRNA was previously associated with AD (in tissue or 
CSF or both) or other neurodegenerative pathology; (3) miRNA is predicted to target genes 
critical to AD pathways (e.g., MAPTau, BACE1); (4) miRNA belongs to miR-15/107 or 
miR-29 family which are hypothesized to be perturbed and/or involved in neurodegenerative 
diseases; (5) miRNA is particularly brain-enriched; (6) miRNA is a potential normalizer 
(CSF housekeeping miRNAs); (7) “contamination” controls; and (8) ubiquitously expressed 
RNA species. MiRNAs that meet at least one of the above criteria were selected for the 
panel. These miRNAs plus U6 were custom-made into a low-density array card, and primers 
for RT and preamplification were prepared by Life Technologies® company.
Performance of CSF-miRNA Panel
To test the performance of the CSF-miRNA panel, the eight CSF samples that were used for 
profiling previously (four ADs, four controls) were tested using the novel platform. The 
CSF-miRNA panel TLDA analysis generated comparable Cq values as that of the inventory 
TaqMan® array cards. The panel seemed to be more sensitive as the overall average Cq was 
2.4 lower than that of the inventory cards (Suppl. Table 3). There was a generally good 
correlation of miRNAs detected by both methods as indicated by Pearson correlation 
coefficient R squared (R2) (Fig. 5, Suppl. Table 3). However, several miRNAs showed a 
discrepancy which could be a result of a difference in primer pool size. Furthermore, primer 
interaction was observed with the custom-made CSF-miRNA panels (data not shown).
Detection of Tissue miRNAs Using CSF-miRNA Panel
RNA samples derived from the human hippocampus (two cases), cerebellum (two cases), 
and choroid plexus (four cases) and snap-frozen at autopsy and clinical blood drawn in a 
clinic and then frozen (two cases) were subjected to CSF-miRNA panel TLDA analysis. 
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Although total RNA is much more abundant in tissue compared with that in CSF and it does 
not require preamplification to obtain a good readout data from these tissue samples, the RT-
qPCR analyses followed the same procedure as that for CSF including the preamplification 
step to maintain the technical consistency. Most miRNAs in the CSF-miRNA panels were 
detected in brain tissues and blood samples. As expected, brain-specific or enriched 
miRNAs in the CSF panel, such as miR-124a, miR-9, and miR-125a, were not detected or 
with very low levels in the blood samples (Suppl. file 3). Several miRNAs displayed similar 
expression patterns in CSF and the choroid plexus (Suppl. file 3). For example, miR-1298 
was detected in CSF and the choroid plexus, but not detected in the blood and cerebellum 
and was very low in the hippocampus; miR-34b and miR-34c also had higher expression 
levels in CSF and the choroid plexus than those in other tested tissues. Neuronal enriched 
miR-124a has a very low level in both CSF and the choroid plexus, as well as in the blood 
samples as expected. Several inflammatory/immunity-related miRNAs, such as miR-21, 
miR-223, miR-150, miR-155, miR-146a, miR-142-5p, and miR-142-3p, were all detected in 
tested brain tissues, but had relatively high levels in CSF and the choroid plexus. In addition, 
miR-204 and miR-1274B seemed to have higher levels in all brain tissues including CSF. 
Hierarchical clustering (Pearson’s distance-Average Linkage) demonstrated that among the 
tested tissues, CSF miRNAs are clustered closely to the choroid plexus (Fig. 6) indicating a 
strong relationship to the organ that generates CSF. Correlation coefficient (R2) of miRNA 
expression pattern between CSF and various tissues (Fig. 7) also indicated a close 
correlation (R2 = 0.4567) between CSF and choroid plexus miRNA expression. A 
comparison of all the correlations between CSF and tissues showed that the correlation 
between miRNAs profiled in CSF and the choroid plexus were statistically significant (p = 
0.019) [27]. The close correlation of CSF miRNA profile with the choroid plexus miRNA 
profile was further confirmed in a separate experiment which was carried out retrospectively 
after the initial evaluations. Using different CSF and tissue samples (Suppl. Fig. 3, Suppl. 
file 4), it was demonstrated that the CSF miRNA profile had a much stronger correlation 
coefficient with that of the choroid plexus (R2 = 0.5694) than with that of the cerebellum (R2 
= 0.1583). The difference between these two correlations was statistically significant (p = 
0.0005) [27].
Discussion
Our study introduces a novel miRNA expression profiling platform designed for relatively 
efficient use in the context of CSF miRNA profiling. We recommend a technical pipeline 
that includes preanalytical parameters, normalization, and expression profile optimization. 
The TLDA returns results that are particularly tailored for the study of CSF miRNAs. We 
found for the first time that CSF miRNA profile is relatively closely correlated with the 
profile of miRNAs in the choroid plexus, in comparison to the samples of the hippocampus 
or cerebellum or blood that we evaluated. Since the TLDA is sensitive and characterized by 
relatively low technical variability and queries miRNAs that previously were shown to be 
relevant to neurodegenerative diseases, it could provide a robust platform for CSF analyses 
in conditions such as AD.
There are potential limitations to the present study. We underscore that there is no perfect 
miRNA profiling technique—because of the low levels of RNA in the CSF, there is a 
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necessary tradeoff of sensitivity and technical variability. We previously have reported some 
of the technical differences that can be seen when data from different profiling platforms are 
compared [22, 29, 30]. Further, the use of TLDA cards lacks the ability of some other 
methods (such as RNA-Seq) to detect novel miRNAs, being limited to the 47 miRNAs on 
the array card. Yet the panel can be refined to include other newly discovered miRNA 
biomarkers when necessary. Finally, there are imperfections in the RNA amplification 
especially when the primers were multiplexed. For all the limitations of any given method, 
we note that there now have been a number of prior studies of CSF miRNAs and other 
biofluid miRNA detection methods were reported previously [13–19], providing incentive 
for the field to achieve a standardized approach.
Among the available miRNA profiling platforms, RT-qPCR is relatively sensitive and 
economically viable. This method is particularly useful when the RNA input is limited, such 
as in the case of CSF RNA. There are two distinct miRNA RT-qPCR platforms currently 
widely used in the field. TaqMan® miRNA RT-qPCR assay (Life Technologies) employs a 
sequence-specific stem-loop RT primer to generate miRNA cDNA template followed by 
qPCR using sequence-specific primers and probes for quantification. Another type of 
platform uses a universal tailing and reverse transcription reaction followed by qPCR with 
sequence-specific PCR primers. The first method proves to be more specific while the latter 
is more sensitive, but less specific [31]. We chose TaqMan® miRNA RT-qPCR assay (Life 
Technologies) as our detection platform for its high specificity. Here, we reported results 
using TaqMan® Array Human MicroRNA A and B cards to profile eight clinical (four 
controls and four ADs) CSF miRNAs.
Our qPCR array profiling detected 193 miRNAs, ~25% of miRNA species spotted on A and 
B cards (which tested a total 766 miRNAs). This is fewer than the detectable miRNAs 
obtained by Denk and the colleagues who profiled CSF miRNA using similar TaqMan® RT-
qPCR-based OpenArray platform [19] which can profile more miRNAs at once (1178 
miRNAs of OpenArray vs 766 of miRNA array Card A and B combined). However, most of 
the detectable miRNA in our profiling were also detected in OpenArray platform. The main 
purpose of this profiling was to provide necessary information with regard to detectability, 
abundance, and potential normalizers for the design of an optimized CSF-miRNA panel. 
Among the detectable miRNAs, several miRNAs, such as miR-1274B, miR-30b, and 
miR-30c, showed little variation from case to case and were each relatively abundant in CSF 
(Cq less than 30). These miRNAs were identified as potential normalizers in the panel. 
Notably, miR-1274B was also suggested as a potential normalizer by Denk et al. [19].
We conclude that TLDA-based PCR assays provide a relatively robust and sensitive platform 
for CSF miRNA analyses. Most prior studies have focused on “endpoints” rather than 
optimizing technical parameters. Here, we evaluated separate RNA isolation techniques and 
RNA carriers. The TLDA panel we propose incorporates the miRNAs highlighted as 
potentially important by prior studies and provides a context for further study. This 
constitutes a relatively high throughput assay that enables potential study design with greater 
numbers of clinical controls—including cognitively intact individuals with and without 
pathologic changes, as well as dementia controls with a variety of different conditions 
reflecting the common brain diseases of aging. Finally, we found it interesting that the 
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miRNA profile of CSF more closely resembled (among the samples tested) those of the 
choroid plexus than those of either brain tissues or blood. MiRNAs are very powerful and 
promiscuous agents that regulate global gene expression. Our findings raise the provocative 
hypothesis that the choroid plexus can influence CNS cells via secretion of miRNAs into the 
CSF, a mechanism that could contribute to both healthy and diseased states in the brain.
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Fig. 1. 
Workflow for testing CSF RNA isolation methods
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Fig. 2. 
Consistency of CSF RNA isolation methods. Four replicate isolations were carried out using 
the same CSF sample for each isolation method. The isolated CSF RNAs were tested using 
the miR-15/107 TLDA analysis. Cq data of each array were plotted against each other, and 
the coefficient of correlation (R2) of the two data sets calculated. A representative plot from 
each method was shown. RNA isolations within each method (a) were highly consistent, 
with slightly higher variance between the different isolation methods (b) with variance being 
greater at low-quantity (high-Cq) miRNAs
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Fig. 3. 
Preamplification increases the detection sensitivity MiR-15/107 TLDA analysis of cDNA 
template generated from the same RT product with or without preamplification are shown. 
The Cq of most miRNAs from the templates without preamplification (red dots and line) in 
miR-15/107 TDLA cards fell to the background (gray dots and line) level (Cq = 35); in 
contrast, preamplification array (brown dots and line) improved detection by several Cq 
values
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Fig. 4. 
CSF miRNA profiling using TaqMan® Array Human MicroRNA A+B Cards (Set v3.0). 
Eight clinical lumbar puncture-harvested CSF (four ADs and four controls) were subject to 
miRNA TaqMan® Array. Overall expression level of miRNAs was slightly lower in AD 
patients (the higher the Cq the lower the expression level)
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Fig. 5. 
Detection of miRNA using CSF-miRNA panel is comparable with inventory TaqMan® 
Array Cards. The same eight clinical lumbar puncture-harvested CSF RNAs were analyzed 
using inventory array cards and customized CSF-miRNA TLDA panel. Cq data of the same 
miRNAs (a, b) and same cases (c, d) generated by CSF-miRNA panel were generally well 
correlated with that of inventory array cards
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Fig. 6. 
Hierarchical clustering of miRNA expression in CSF, blood, and tissue RNA was analyzed 
using CSF-miRNA TLDA. Cq values of each array were normalized by global mean 
method. Hierarchical clustering of expression patterns was determined by Pearson’s 
distance-average linkage. The heatmap indicated that miRNA patterns of CSF were 
relatively similar to that of the choroid plexus, the organ that generates CSF. CSF, blood, 
hippocampus, and cerebellum samples are marked in the same colors
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Fig. 7. 
Correlation of miRNAs detected in CSF and tissues using CSF-miRNA panel CSF and 
tissue RNAs was analyzed using CSF-miRNA TLDA. Average Cq values of each sample 
group were plotted against each other, and the coefficient correlation (R2) of two data sets 
were obtained by linear regression
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Table 1
Comparison of CSF RNA isolated by various methods on miR-15/107 TLDA cards (n = 4)
Isolation
method
Carrier Carrier only w/
PreAmp
CSF RNA w/o
PreAmp
CSF RNA w/
PreAmp
ΔCq above
background
miRNeasy MS2 32.77 32.93 25.34 −7.44
miRCURY MS2 32.95 33.25 26.12 −6.82
TRIzol LS MS2 33.14 N.D. 25.89 −7.25
Glycogen 33.93 N.D. 26.77 −7.16
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Table 2
Consistency of RNA isolation by each method (n = 4)
Average Cq STDEV STDEV range
miRNeasy 25.66 0.65 0.21–1.94
miRCURY 26.08 0.77 0.14–3.04
TRIzol LS 27.09 0.48 0.16–2.31
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Table 3
Isolation method comparison
Isolation method RNA Easiness Organic solvent Time
miRCURY Good +++ No Fast
miRNeasy Good ++ Yes Fair
Trizol LS Good − Yes Lengthy
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Table 4
Top 50 most abundant miRNAs in CSF identified by TaqMan® miRNA RT-qPCR arrays
Rank miRNA Cq Rank miRNA Cq
1 hsa-miR-204 24.4 26 hsa-let-7b 29.3
2 hsa-miR-1274B 25.3 27 hsa-miR-92a 29.4
3 hsa-miR-17 26.6 28 hsa-miR-20a 29.5
4 hsa-miR-106a 26.8 29 hsa-miR-211 29.5
5 hsa-miR-19b 27.0 30 hsa-miR-425-5p 29.6
6 hsa-miR-223 27.1 31 hsa-miR-99a 29.6
7 hsa-miR-1298 27.3 32 hsa-miR-30b 29.6
8 hsa-miR-720 27.5 33 hsa-miR-484 29.7
9 hsa-miR-21 27.6 34 hsa-miR-571 29.7
10 hsa-miR-661 27.8 35 hsa-miR-29a 29.8
11 hsa-miR-146a 28.1 36 hsa-miR-100 29.9
12 hsa-miR-150 28.2 37 hsa-miR-346 29.9
13 hsa-miR-30a-5p 28.5 38 hsa-miR-1274A 29.9
14 hsa-miR-9# 28.5 39 hsa-miR-338-5P 30.0
15 hsa-miR-24 28.6 40 hsa-miR-638 30.1
16 hsa-miR-320 28.6 41 hsa-miR-574-3p 30.1
17 hsa-miR-34b 28.7 42 hsa-miR-125b 30.2
18 hsa-miR-30c 28.8 43 hsa-miR-485-3p 30.2
19 hsa-miR-16 28.8 44 hsa-miR-146b 30.3
20 hsa-miR-1825 28.9 45 hsa-miR-26a 30.3
21 hsa-miR-487a 29.1 46 hsa-miR-885-5p 30.3
22 hsa-miR-222 29.1 47 hsa-miR-143 30.4
23 hsa-miR-342-3p 29.1 48 hsa-miR-34a 30.4
24 hsa-miR-30a-3p 29.2 49 hsa-miR-1275 30.5
25 hsa-miR-648 29.3 50 hsa-miR-145 30.5
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Table 5
Top 10 most stable miRNAs in CSF
miRNA Rank Cq-AD STDEV-AD Cq-ctrl STDEV-ctrl Cq-all STDEV-all
hsa-miR-152 88 32.0 0.14 32.0 0.19 32.0 0.16
hsa-miR-618 89 32.0 0.38 32.0 0.06 32.0 0.26
hsa-miR-30c 18 28.6 0.07 29.0 0.22 28.8 0.27
hsa-miR-9# 14 28.6 0.31 28.4 0.26 28.5 0.28
hsa-miR-208 193 34.8 0.50 34.9 0.15 34.8 0.35
hsa-miR-1274B 2 25.3 0.20 25.4 0.50 25.3 0.35
hsa-miR-30a-5p 13 28.6 0.41 28.4 0.38 28.5 0.38
hsa-miR-204 1 24.2 0.17 24.7 0.39 24.4 0.39
hsa-miR-30b 32 29.5 0.42 29.7 0.39 29.6 0.40
hsa-miR-338-5P 39 29.9 0.37 30.1 0.48 30.0 0.42
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Table 6
Specific CSF miRNA panel for studying neurodegenerative diseases
Assay ID miRNA Selection criteria Note
000377 hsa-let-7a 1, 8 ND in our array
002619 hsa-let-7b 1, 8
000379 hsa-let-7c 1, 8
000382 hsa-let-7f 1, 2, 8 ND in our array
000439 hsa-miR-103 1, 2, 3, 4
002169 hsa-miR-106a 1, 2, 3, 4
000443 hsa-miR-107 1, 2, 3 ND in our array
000449 hsa-miR-125b 1, 2, 5
002884 hsa-miR-1274B 1, 6
002861 hsa-miR-1298 1, 2
000457 hsa-miR-132 1, 2, 3
000464 hsa-miR-142-3p 1, 2
002248 hsa-miR-142-5p 1
000468 hsa-miR-146a 1, 2
001097 hsa-miR-146b 1, 2
000473 hsa-miR-150 1
002623 hsa-miR-155 1, 2
000389 hsa-miR-15a 1, 2, 3, 4 ND in our array
000390 hsa-miR-15b 1, 2, 3, 4
000391 hsa-miR-16 1, 2, 3, 4
002308 hsa-miR-17 1, 3
000480 hsa-miR-181a 1, 2 ND in our array
000482 hsa-miR-181c 1, 2 ND in our array
000494 hsa-miR-195 1, 2, 3, 4
000396 hsa-miR-19b 1, 2, 3
000508 hsa-miR-204 1, 3, 6
000580 hsa-miR-20a 1, 3
000397 hsa-miR-21 1, 2, 7
002295 hsa-miR-223 1, 2, 7
000402 hsa-miR-24 1, 7
000408 hsa-miR-27a 1, 2
002112 hsa-miR-29a 1, 2, 4
000413 hsa-miR-29b 1, 2, 4 ND in our array
000587 hsa-miR-29c 1, 2, 4
000416 hsa-miR-30a-3p 1, 2, 6
000417 hsa-miR-30a-5p 1, 2
000602 hsa-miR-30b 1, 2, 6
000419 hsa-miR-30c 1, 2, 6
000420 hsa-miR-30d 1, 2
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Assay ID miRNA Selection criteria Note
000422 hsa-miR-30e-3p 1
000426 hsa-miR-34a 1, 2
002102 hsa-miR-34b 1, 2
000428 hsa-miR-34c 1, 2
001043 hsa-miR-497 1, 2, 3, 4
000583 hsa-miR-9 1, 2, 5 ND in our array
001182 mmu-miR-124a 1, 2, 5 ND in our array
001141 mmu-miR-451 1, 2
1 miRNA is detectable in CSF based on our profiling and existing literature, 2 miRNAwas previously associated with AD (in tissue or CSF or both) 
or other neurodegenerative pathology, 3 miRNA is predicted to target genes critical to AD pathways (e.g., MAPTau, BACE1), 4 miRNA belongs to 
miR-15/107 or miR-29 family which are hypothesized to be perturbed and/or involved in neurodegenerative diseases, 5 miRNA is particularly 
brain-enriched, 6 miRNA is a potential normalizer (CSF housekeeping miRNAs), 7 contamination controls, 8 ubiquitously expressed RNA species, 
ND not detected
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